This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Chemotherapy-Induced Oral Mucositis Market

Market Insights on Chemotherapy-Induced Oral Mucositis covering sales outlook, demand forecast & up-to-date key trends

Chemotherapy-Induced Oral Mucositis Market : Global Industry Analysis 2016 - 2020 and Opportunity Assessment 2021 - 2031

Chemotherapy-Induced Oral Mucositis Market Overview

According to the latest research by Future Market Insights, chemotherapy-induced oral mucositis market is set to experience positive growth during the year 2021-2031. The global oral mucositis market is witnessing demand every year as cases of oral mucositis become apparent each year.

This demand fluctuates from year to year based on a variety of conditions. This market covers the prescription and sales of oral mucositis drugs worldwide. Oral mucositis is swelling of the tissues of the oral cavity. This medical condition occurs as a common side effect of radiation or chemotherapy.

Oral mucositis is a common health problem caused by cancer treatment and other factors, so this market faces demand in many parts of the world. Therefore, the customer base of oral mucositis in the global market is diversified. Increase in usage of chemotherapeutic agents due to increasing incidence of cancers is the major growth driver of chemotherapy-induced oral mucositis treatment market.

What is Driving Demand for Chemotherapy-Induced Oral Mucositis Market?

There are many growing drivers of the oral mucositis market that frequently affect the market. One of the major driver in the oral mucositis market is the increased detection of cancer. This is also the case for the discovery of cases of head and neck cancer. In recent years, the number of patients with cancer has increased.

This also creates a window for oral mucositis and industrial demand window for oral mucositis. Another important factor in the oral mucositis market is the increased elderly population. People get older and more susceptible to cancer because of their current lifestyle.

These factors also affect the oral mucositis market as the increase in the number of patients receiving chemotherapy each year. Increasing prevalence of cancer propel the growth of Chemotherapy-Induced Oral Mucositis Market.

Customize this Report

Let us know your requirement to get
100% FREE customization

Increasing Incidence of Oral Mucositis Likely to Augment Chemotherapy-Induced Oral Mucositis Sales

Chemotherapy treatment causes oral mucositis in 35% of patients. The incidence of oral mucositis was particularly high in patients with tumours in the oropharynx or nasopharynx, patients receiving concomitant chemotherapy, patients with total doses greater than 5000 cGy, and patients. Treated with an altered split radiation schedule.

Enzychem Lifesciences, has a mid-term experimental oral compound called EC18 for OM induced by chemoradiation therapy.

U.S. And Canada Chemotherapy-Induced Oral Mucositis Market Outlook

About half a million people in the United States suffer from oral mucositis each year, and oral mucositis represents a new market in which unmet health care needs are largely intrinsically a long-standing problem. It is estimated that 40% of cancer patients who receive standard chemotherapy will develop oral mucositis.

The Centres for Disease Control and Prevention estimates that approximately 650,000 cancer patients in the United States receive chemotherapy in an outpatient environment each year.Generally speaking, there is an agreement that there are about 500,000 oral mucositis cases each year in the United States today. Adding financial burden makes the market opportunity to solve oral mucositis clearer.

Innovation Pharma evaluated Buriracizine in a fast-track designation in a gargle, Phase II clinical trial to reduce oral mucositis in patients with head and neck cancer (HNC) who received chemo radiation therapy. NCI scientists developed palifermin, a very successful treatment for preventing and treating oral mucositis.

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

Europe Demand Outlook For C Hemotherapy-Induced Oral Mucositis

Mucositis is a common complication of chemotherapy, radiation therapy, and targeted formulations. This often affects chemotherapy compliance because it induces schedule delays, treatment interruptions or discontinuations. Also, the economic impact associated with the management of mucositis is local, and some estimates of additional hospital costs due to these clinical conditions have recently been reported.

The ability to determine risk factors for mucositis, detect early onset, accurately assess the degree of toxicity, and plan multidisciplinary management ensures quality of life for all patients and of this drug it is an important factor in avoiding unnecessary capacity reduction or discontinuation in the treatment.

BMG Pharma in 2018 got the European regulatory approval for its GelX product to be used for the prevention of oral mucositis. episil® (Camurus AB) oral liquid – a treatment for intraoral pain caused by oral mucositis

Who Are The Key Manufacturers And Suppliers of Chemotherapy-Induced Oral Mucositis Market?

Some of the key players operating in the Chemotherapy-Induced Oral Mucositis Market are

  • Izun Pharmaceuticals
  • Soleva Pharma
  • Aurora Bioscience
  • INNOVATION Pharma
  • Camurus AB
  • Monopar Therapeutics
  • Prothex Inc.
  • Access Pharmaceutical Inc.
  • Swedish Orphan Biovitrum AB
  • NeoMedLight

MuGard®, Soleva Pharma Oral mucoadhesive is indicated for the management of oral mucositis/stomatitis and all kinds of oral wounds (inflammation and damage) including inflammation/ulcer pain and traumatic ulcers. As a result of intraoral surgery or improper fit of dentures or braces.

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Key Segment

By Treatment Type:

  • Ice Chips(Cryotherapy)
  • Preventive And Supportive Dental Care
  • Strong Oral Cleaning Procedures
  • Gels/Rinses

By Distribution Channel:

  • Hospitals
  • Oncology Centres
  • Research Institutes
  • Dental Clinics
  • Others

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • The Middle East and Africa
Table of Content

NA

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

NA

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst
List of Charts

NA

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports
Google translate

Chemotherapy-Induced Oral Mucositis Market